Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 346 7764

Website: www.psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada

TheRoaringBunny Dec. 25 at 1:33 AM

$PBM $FLGC $SMX $SOPA $DRMA discord . gg / hotstocks 100% free female led trading discord Focused on asymmetric multibaggers

0 · Reply

ParabolicalSpartan Dec. 24 at 3:13 PM

What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems Accumulatiiion $ATCH $OPEN $PBM $GPUS

0 · Reply

Joby099 Dec. 24 at 2:09 AM

$PBM $FLGC $CWAN

0 · Reply

SunnySky100 Dec. 23 at 5:43 PM

$PBM Maybe above $1 in the AH?

0 · Reply

Fede_Tech Dec. 23 at 5:33 PM

$PBM I'm back in at $0.92 I hope I can recover some losses here.

0 · Reply

Rampageusa Dec. 23 at 5:30 PM

$PCSA, $PBM Consolidating, expect a boom soon in few days or today, same for $CETX… Is that P letter ralated stocks day today..?

0 · Reply

GameArcher Dec. 23 at 5:27 PM

$PBM 314k shares purchased at $1.65 per share per 13D filed 12/10 — typical drop to acquire more before the big move up.

0 · Reply

RuddyRolls Dec. 23 at 5:17 PM

$PBM accumulate

0 · Reply

SunnySky100 Dec. 23 at 4:42 PM

$PBM News???

0 · Reply

Alarusso68 Dec. 23 at 4:35 PM

$PBM looks like the bleeding has stopped! She's going up!

0 · Reply

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 9, 2025, 7:00 AM EST - 15 days ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Nov 25, 2025, 7:00 AM EST - 4 weeks ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 20, 2025, 7:00 AM EST - 4 weeks ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 12, 2025, 7:00 AM EST - 6 weeks ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 6, 2025, 7:00 AM EST - 6 weeks ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 3, 2025, 7:00 AM EST - 7 weeks ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Aug 28, 2025, 8:00 AM EDT - 4 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 5 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 6 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 6 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 6 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 6 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 7 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 8 months ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 8 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 8 months ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 9 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 9 months ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 9 months ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 10 months ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 10 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 10 months ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Oct 14, 2024, 10:43 AM EDT - 1 year ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Oct 4, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Sep 20, 2024, 11:20 AM EDT - 1 year ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Sep 19, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Sep 18, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 16, 2024, 9:31 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 13, 2024, 4:30 PM EDT - 1 year ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 6, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

TheRoaringBunny Dec. 25 at 1:33 AM

$PBM $FLGC $SMX $SOPA $DRMA discord . gg / hotstocks 100% free female led trading discord Focused on asymmetric multibaggers

0 · Reply

ParabolicalSpartan Dec. 24 at 3:13 PM

0 · Reply

Joby099 Dec. 24 at 2:09 AM

$PBM $FLGC $CWAN

0 · Reply

SunnySky100 Dec. 23 at 5:43 PM

$PBM Maybe above $1 in the AH?

0 · Reply

Fede_Tech Dec. 23 at 5:33 PM

$PBM I'm back in at $0.92 I hope I can recover some losses here.

0 · Reply

Rampageusa Dec. 23 at 5:30 PM

$PCSA, $PBM Consolidating, expect a boom soon in few days or today, same for $CETX… Is that P letter ralated stocks day today..?

0 · Reply

GameArcher Dec. 23 at 5:27 PM

$PBM 314k shares purchased at $1.65 per share per 13D filed 12/10 — typical drop to acquire more before the big move up.

0 · Reply

RuddyRolls Dec. 23 at 5:17 PM

$PBM accumulate

0 · Reply

SunnySky100 Dec. 23 at 4:42 PM

$PBM News???

0 · Reply

Alarusso68 Dec. 23 at 4:35 PM

$PBM looks like the bleeding has stopped! She's going up!

0 · Reply

johnlesser Dec. 23 at 4:24 PM

$PBM offerer a free sample of your product to investors

0 · Reply

johnny6nine Dec. 23 at 4:19 PM

$PBM run it!

0 · Reply

St0ckPwn Dec. 23 at 2:16 PM

$PBM 1.70M market cap with 9M cash with no debt is quite crazy 😂 never seen a ticker this disconnected

2 · Reply

Joby099 Dec. 23 at 2:14 PM

$PBM $FLGC $CWAN

0 · Reply

johnny6nine Dec. 23 at 2:08 PM

$PBM easy 100% from wherever this ends up settling

0 · Reply

Spartan117x Dec. 23 at 5:25 AM

$PBM This stock pops and tanks too fast its not normal, not even shorts. Massive company dilution imo on every pop, if they advertise 9M cash, why keep diluting so hard for more money? Toxic management with 42 of 50 reverse split still available to use. Not sure they will change tactics any time soon. Chart is a total nightmare, all downhill

0 · Reply

Joby099 Dec. 23 at 1:54 AM

$PBM $FLGC $CWAN

0 · Reply

SunnySky100 Dec. 23 at 12:24 AM

$PBM NO DEBT

1 · Reply

Planet07 Dec. 23 at 12:21 AM

$PBM heading to fill my order.40c .

0 · Reply

SunnySky100 Dec. 22 at 10:50 PM

$PBM Longevity research program is being launched.

0 · Reply

FullPorrtDipz Dec. 22 at 7:55 PM

If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Increasing position on $CLOV $RVSN $PBM $KTOS too

0 · Reply

BigALB Dec. 22 at 5:19 PM

$PBM another country added to the list GLTA https://www.forbes.com/sites/sarahsinclair/2025/12/15/czech-republic-approves-regulations-for-medical-use-of-psilocybin/ 🎄

0 · Reply

Market Cap	1.74M
Revenue (ttm)	0.00
Net Income (ttm)	1.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	270,400
Avg Vol	1,626,792
Day's Range	N/A - N/A
Shares Out	1.87M
Stochastic %K	11%
Beta	0.28
Analysts	Strong Buy
Price Target	N/A